Jeffrey S. Weber spends much of his time researching Melanoma, Internal medicine, Ipilimumab, Surgery and Immunology. His studies in Melanoma integrate themes in fields like Intention-to-treat analysis, Blockade, Hazard ratio, Interleukin 2 and Surrogate endpoint. Internal medicine is often connected to Oncology in his work.
His Ipilimumab study combines topics in areas such as Adjuvant, Adverse effect and Clinical trial. His biological study spans a wide range of topics, including Cancer, Chemotherapy and Talimogene laherparepvec. His work carried out in the field of Surgery brings together such families of science as Gastroenterology, Placebo and Nivolumab.
Jeffrey S. Weber mainly investigates Melanoma, Internal medicine, Oncology, Cancer research and Ipilimumab. Jeffrey S. Weber combines subjects such as Immunology, Cancer, Immune system, Immunotherapy and Gastroenterology with his study of Melanoma. The Nivolumab, Adverse effect and Clinical trial research Jeffrey S. Weber does as part of his general Internal medicine study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
His Oncology study incorporates themes from Pembrolizumab, Regimen, Advanced melanoma and Immune checkpoint inhibitors. His work on Metastatic melanoma as part of general Cancer research research is often related to HDAC6, thus linking different fields of science. Jeffrey S. Weber focuses mostly in the field of Ipilimumab, narrowing it down to matters related to Adjuvant therapy and, in some cases, Hazard ratio.
Jeffrey S. Weber mostly deals with Melanoma, Internal medicine, Oncology, Cancer research and Immunotherapy. While the research belongs to areas of Melanoma, Jeffrey S. Weber spends his time largely on the problem of Immune checkpoint inhibitors, intersecting his research to questions surrounding Advanced melanoma, Toxicity and Bioinformatics. Ipilimumab, Cancer, Adverse effect, Adjuvant therapy and Pembrolizumab are the core of his Internal medicine study.
His Ipilimumab study integrates concerns from other disciplines, such as Clinical endpoint, Randomized controlled trial, Placebo, Complete resection and Nivolumab. His work is dedicated to discovering how Oncology, Clinical trial are connected with Vemurafenib and other disciplines. His Cancer research research focuses on Immune system and how it relates to Flow cytometry.
The scientist’s investigation covers issues in Melanoma, Internal medicine, Oncology, Cancer research and Immunotherapy. His Melanoma research is multidisciplinary, incorporating perspectives in Immune checkpoint, Blockade, Chemotherapy, Acute-phase protein and Autoimmunity. In general Internal medicine, his work in Ipilimumab, Hazard ratio, Adjuvant therapy and Rash is often linked to In patient linking many areas of study.
Jeffrey S. Weber has included themes like Gastroenterology, Nivolumab, Adverse effect and Clinical endpoint in his Ipilimumab study. His Oncology research incorporates themes from Pembrolizumab, Cancer and Overweight, Obesity. His Immunotherapy study combines topics from a wide range of disciplines, such as Interleukin 6, CTLA-4, Antigen presentation and Antigen.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber.
The New England Journal of Medicine (2010)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day.
The New England Journal of Medicine (2011)
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi.
The New England Journal of Medicine (2013)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok;Axel Hoos;Steven O'Day;Jeffrey S. Weber.
Clinical Cancer Research (2009)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty;Jeffery R. Infante;Adil Daud;Rene Gonzalez.
The New England Journal of Medicine (2012)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi.
Lancet Oncology (2015)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins.
Journal of Clinical Oncology (2018)
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez.
The New England Journal of Medicine (2012)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf;F. Stephen Hodi;Caroline Robert;Jeffrey S. Weber.
Journal of Clinical Oncology (2015)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi.
The Lancet (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: